S
2.19
0.09 (4.29%)
| Previous Close | 2.10 |
| Open | 2.12 |
| Volume | 1,105,394 |
| Avg. Volume (3M) | 1,486,665 |
| Market Cap | 378,513,024 |
| Price / Book | 2.40 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -0.490 |
| Total Debt/Equity (MRQ) | 20.08% |
| Current Ratio (MRQ) | 14.91 |
| Operating Cash Flow (TTM) | -95.63 M |
| Levered Free Cash Flow (TTM) | -56.02 M |
| Return on Assets (TTM) | -38.97% |
| Return on Equity (TTM) | -75.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Savara, Inc. | Bearish | Bearish |
AIStockmoo Score
1.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.25 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.38% |
| % Held by Institutions | 98.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Guggenheim, 265.30%) | Buy |
| Median | 4.50 (105.48%) | |
| Low | 2.00 (HC Wainwright & Co., -8.68%) | Hold |
| 2.00 (Evercore ISI Group, -8.68%) | Hold | |
| Average | 4.75 (116.90%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 2.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 29 May 2025 | 2.00 (-8.68%) | Hold | 2.24 |
| Evercore ISI Group | 28 May 2025 | 2.00 (-8.68%) | Hold | 2.14 |
| Guggenheim | 28 May 2025 | 8.00 (265.30%) | Buy | 2.14 |
| Wells Fargo | 28 May 2025 | 7.00 (219.63%) | Buy | 2.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 May 2025 | Announcement | Savara Announces Participation in Jefferies Global Healthcare Conference |
| 18 May 2025 | Announcement | Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 |
| 13 May 2025 | Announcement | Savara Reports First Quarter 2025 Financial Results and Provides a Business Update |
| 12 May 2025 | Announcement | Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference |
| 01 May 2025 | Announcement | Savara Announces Participation in the Upcoming Citizens Life Sciences Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |